View:
Download DOC
Download PDF
Download XLS

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

(Amendment No. )

 

Kinnate Biopharma Inc.

(Name of Issuer)

 

Common Stock $0.0001 par value

(Title of Class of Securities)

 

49705R 10 5

(CUSIP Number)

 

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

 

¨Rule 13d-1(c)

 

xRule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

1 NAMES OF REPORTING PERSONS
Nextech V Oncology S.C.S., SICAV-SIF
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)   x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
3,008,243
  6 SHARED VOTING POWER
0
  7

SOLE DISPOSITIVE POWER

3,008,243

  8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,008,243
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.9% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

  

(1)This Schedule 13G is filed by Nextech V Oncology S.C.S., SICAV-SIF (“Nextech V LP”), Nextech V GP S.à. r.l. (“Nextech V GP”), Thomas Lips (“Lips”) and Dalia Bleyer (“Bleyer” and together with Nextech V LP, Nextech V GP and Lips, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 43,327,219 shares of common stock outstanding following the closing of its initial public offering as of December 7, 2020, as disclosed in the Issuer’s final prospectus for its initial public offering, as filed with the Securities and Exchange Commission on December 3, 2020.

 

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

1 NAMES OF REPORTING PERSONS
Nextech V GP S.à r.l.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
3,008,243
  6 SHARED VOTING POWER
0
  7

SOLE DISPOSITIVE POWER

3,008,243

  8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,008,243
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.9% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 43,327,219 shares of common stock outstanding following the closing of its initial public offering as of December 7, 2020, as disclosed in the Issuer’s final prospectus for its initial public offering, as filed with the Securities and Exchange Commission on December 3, 2020.

 

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

1 NAMES OF REPORTING PERSONS
Thomas Lips
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
0
  6 SHARED VOTING POWER
3,008,243
  7

SOLE DISPOSITIVE POWER

0

  8 SHARED DISPOSITIVE POWER
3,008,243

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,008,243
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.9% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 43,327,219 shares of common stock outstanding following the closing of its initial public offering as of December 7, 2020, as disclosed in the Issuer’s final prospectus for its initial public offering, as filed with the Securities and Exchange Commission on December 3, 2020.

 

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

1 NAMES OF REPORTING PERSONS
Dalia Bleyer
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Lithuania

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
0
  6 SHARED VOTING POWER
3,008,243
  7

SOLE DISPOSITIVE POWER

0

  8 SHARED DISPOSITIVE POWER
3,008,243

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,008,243
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.9% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 43,327,219 shares of common stock outstanding following the closing of its initial public offering as of December 7, 2020, as disclosed in the Issuer’s final prospectus for its initial public offering, as filed with the Securities and Exchange Commission on December 3, 2020.

 

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”) of Kinnate Biopharma Inc. (the “Issuer”).

 

Item 1(a)Name of Issuer:

 

Kinnate Biopharma Inc.

 

Item 1(b)Address of Issuer’s principal executive offices:

 

11975 El Camino Real, Suite 101
San Diego, CA 92130

 

 

Items 2(a)Name of Reporting Persons filing:

 

  Nextech V Oncology S.C.S., SICAV-SIF (“Nextech V LP”)
  Nextech V GP S.à r.l. (“Nextech V GP”)
  Thomas Lips (“Lips ”)
  Dalia Bleyer (“Bleyer”)

 

Item 2(b)Address or principal business office or, if none, residence:

 

The address of the principal business office: 8 rue Lou Hemmer
  L-1748 Luxembourg-Findel
  Grand-Duché de Luxembourg

 

Item 2(c)Citizenship:

 

Name Citizenship or Place of Organization
Nextech V LP Luxembourg
Nextech V GP Luxembourg
Lips Switzerland
Bleyer Lithuania

 

 

Item 2(d)Title of class of securities:

Common stock, $0.0001 par value

 

Item 2(e)CUSIP No.:

49705R 10 5

 

Item 3If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

 

Not applicable.

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

Item 4Ownership

The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.

 

Reporting Persons  Shares of
Common
Stock Held
Directly		   Sole
Voting
Power		   Shared
Voting
Power (1)		   Sole
Dispositive
Power		   Shared
Dispositive
Power (1)		   Beneficial
Ownership		   Percentage
of Class
(1)(2)		 
Nextech V LP   3,008,243    3,008,243    0    3,008,243    0    3,008,243    6.9%
Nextech V GP (1)   0    3,008,243    0    3,008,243    0    3,008,243    6.9%
Lips (1)   0    0    3,008,243    0    3,008,243    3,008,243    6.9%
Bleyer (1)   0    0    3,008,243    0    3,008,243    3,008,243    6.9%

 

(1)The shares are held by Nextech V LP. Nextech V GP serves as the sole general partner of Nextech V LP and has sole voting and investment control over the shares owned by Nextech V LP and may be deemed to own beneficially the shares held by Nextech V LP. Nextech V GP owns no securities of the Issuer directly. Bleyer and Lips are members of the board of managers of Nextech V GP and share voting and dispositive power over the shares held by Nextech V LP, and may be deemed to own beneficially the shares held by Nextech V LP. The managing members own no securities of the Issuer directly.

(2)This percentage is based on 43,327,219 shares of common stock outstanding following the closing of its initial public offering as of December 7, 2020, as disclosed in the Issuer’s final prospectus for its initial public offering, as filed with the Securities and Exchange Commission on December 3, 2020.

 

Item 5Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ( ).

 

Item 6Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

 

Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

 

Item 8Identification and Classification of Members of the Group

Not applicable.

 

Item 9Notice of Dissolution of Group

Not applicable.

 

Item 10Certifications

Not applicable.

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in the attached statement on Schedule 13G is true, complete and correct.

 

Dated: February 16, 2021

 

Nextech V Oncology S.C.S., SICAV-SIF

 

By: Nextech V GP S.à r.l.
Its: General Partner

 

By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ Thomas Lips  
  Thomas Lips, Managing Member  

 

Nextech V GP S.à r.l.  
     
By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ Thomas Lips  
  Thomas Lips, Managing Member  

 

 

/s/ Thomas Lips  
Thomas Lips  
   
/s/ Dalia Bleyer  
Dalia Bleyer  

 

 

 

 

CUSIP NO. 49705R 10 5 13 G  

 

Exhibit(s):

 

Exhibit 99.1: Joint Filing Statement

 

 

 

 

 


CUSIP No. 49705R 10 5		 13G Exhibit 99.1

 

JOINT FILING STATEMENT

 

We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of Kinnate Biopharma Inc. is filed on behalf of each of us.

 

 

Dated: February 16, 2021

 

 Nextech V Oncology S.C.S., SICAV-SIF

 

By: Nextech V GP S.à r.l.
Its: General Partner

 

By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ Thomas Lips  
  Thomas Lips, Managing Member  

 

Nextech V GP S.à r.l.  
     
By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ Thomas Lips  
  Thomas Lips, Managing Member  

 

 

/s/ Thomas Lips  
Thomas Lips  
   
/s/ Dalia Bleyer  
Dalia Bleyer